Patient selection for immunotherapy in head and neck cancer

Lancet Oncol. 2021 Jul;22(7):e290. doi: 10.1016/S1470-2045(21)00237-0.

Authors

Pierluigi Bonomo¹, Ester Orlandi², Paolo Bossi³

Affiliations

¹ Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
² Radiation Oncology Clinical Department, National Center for Oncological Hadrontherapy, Pavia, Italy.
³ Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health-Medical Oncology, University of Brescia, ASST-Spedali Civili, Brescia 25123, Italy. Electronic address: [email protected].

PMID: 34197752
DOI: 10.1016/S1470-2045(21)00237-0

No abstract available

Publication types

Letter
Comment

MeSH terms

Head and Neck Neoplasms* / therapy
Humans
Immunologic Factors
Immunotherapy / adverse effects
Patient Selection

Substances

Immunologic Factors